OTTAWA, ON, June 25, 2021 /CNW/ - Tetra Bio-Pharma
Inc.
("Tetra"
or
the "Company")
(TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in
cannabinoid-derived drug discovery and development,
announced today that Jean-François Boily has resigned as
Chief Financial Officer of the Corporation effective July 16th, 2021 to pursue another
business opportunity. Tetra has commenced an executive search for a
new Chief Financial Officer. The Company intends to use
its internal finance team and to retain the services of a
consultant to serve as CFO in order to ensure that all financial
reporting obligations of the Company are fulfilled while the
Company identifies a suitable candidate to replace Mr. Boily. Tetra
will update the market in due course.
"On behalf of the Board of Directors, I thank
Jean-François for his contributions to Tetra over the last 9
months" said Guy Chamberland, Chief
Executive Officer of Tetra. "We wish him every success moving
forward."
About Tetra Bio-Pharma Inc.:
Tetra Bio-Pharma (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) is a
leader in cannabinoid-derived drug discovery and development with a
FDA and a Health Canada cleared clinical program aimed at bringing
novel prescription drugs and treatments to patients and their
healthcare providers. Our evidence-based scientific approach has
enabled us to develop a pipeline of cannabinoid-based drug products
for a range of medical conditions, including pain, inflammation,
and oncology. With patients at the core of what we do, Tetra
Bio-Pharma is focused on providing rigorous scientific validation
and safety data required for inclusion into the existing biopharma
industry by regulators, physicians and insurance
companies.
For more information visit:
www.tetrabiopharma.com
SOURCE Tetra Bio-Pharma Inc.